STOCK TITAN

AstraZeneca Baxfendy recommended for EU approval

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

AstraZeneca PLC (AZN) said the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended Baxfendy (baxdrostat) for EU approval for adults whose arterial hypertension remains insufficiently controlled with at least two antihypertensive medicines. If approved, Baxfendy would be the first and only aldosterone synthase inhibitor in the EU. The recommendation follows two Phase III trials in people with uncontrolled or resistant hypertension.

In BaxHTN, the 2 mg dose reduced mean seated systolic blood pressure by 15.7 mmHg from baseline at week 12; the placebo-adjusted reduction was 9.8 mmHg. In Bax24, the 2 mg dose reduced 24-hour average ambulatory systolic pressure by 16.6 mmHg from baseline, with a 14.0 mmHg placebo-adjusted reduction. At week 12, 70.6% of Baxfendy-treated Bax24 participants reached an ambulatory 24-hour average systolic pressure below 130 mmHg, compared with 16.7% on placebo. The company said Baxfendy was generally well-tolerated in the trials, with no unanticipated safety findings.

BaxHTN seated systolic blood pressure reduction from baseline 15.7 mmHg Baxfendy 2 mg at week 12
BaxHTN placebo-adjusted seated systolic blood pressure reduction 9.8 mmHg Baxfendy 2 mg at week 12
Bax24 ambulatory 24-hour average systolic blood pressure reduction from baseline 16.6 mmHg Baxfendy 2 mg at week 12
Bax24 placebo-adjusted ambulatory 24-hour average systolic blood pressure reduction 14.0 mmHg Baxfendy 2 mg at week 12
Reached ambulatory 24-hour average systolic pressure below 130 mmHg 70.6% Baxfendy group in Bax24 at week 12
Reached ambulatory 24-hour average systolic pressure below 130 mmHg 16.7% Placebo group in Bax24 at week 12
Committee for Medicinal Products for Human Use regulatory
"The Committee for Medicinal Products for Human Use (CHMP) of the EMA"
The Committee for Medicinal Products for Human Use is the expert scientific panel within the European medicines regulator that assesses whether medicines for people are safe, effective and of acceptable quality, and issues formal opinions used in the drug-approval process. Its assessments act like a gatekeeper or safety inspector for entering the European market, so the committee’s opinion can materially affect a drug’s commercial prospects, regulatory risk and a company’s stock valuation.
aldosterone synthase inhibitor medical
"first and only aldosterone synthase inhibitor in the EU"
Aldosterone synthase inhibitors are drugs that reduce production of the hormone aldosterone, which helps control salt, water balance, and blood pressure. Think of them as turning down a faucet that feeds excess blood pressure and fluid buildup; by lowering aldosterone they can ease strain on the heart and kidneys. Investors track these drugs because trial results, regulatory approval, and safety can materially affect a developer’s revenue outlook and stock value.
placebo-adjusted reduction medical
"the placebo-adjusted reduction was 9.8 mmHg"
The measured amount by which a treatment reduces a symptom, event rate, or biomarker after subtracting the change seen in the placebo group; it isolates the drug’s effect from improvements that occur simply because people think they are being treated. Investors care because it shows the treatment’s true incremental benefit over no active therapy, much like comparing a new tire’s extra mileage to that of a standard tire rather than to zero.
ambulatory 24-hour average SBP medical
"change from baseline in ambulatory 24-hour average SBP"
resistant hypertension medical
"patients with resistant hypertension"
A form of high blood pressure that stays above the recommended target despite taking multiple different blood-pressure medicines, often including a diuretic (a “water pill”), or that needs four or more drugs to control. Think of it like a car that keeps accelerating even after you try several different brakes; it signals a stubborn medical problem and a clear unmet need. For investors, resistant hypertension matters because it creates demand for new drugs, devices, or care approaches, shapes clinical trial design and regulatory hurdles, and can affect long-term sales potential and healthcare costs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is AZN’s Baxfendy status in the EU?

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended Baxfendy for EU approval for adults whose arterial hypertension remains insufficiently controlled with at least two antihypertensive medicines. The recommendation is not an EU approval; the company said that, if approved, Baxfendy would be the first and only aldosterone synthase inhibitor in the EU.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of November 2026 
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 

 
AstraZeneca PLC
 
INDEX TO EXHIBITS
 
 
1.
Baxfendy recommended for approval in the EU
 
 
 16 November 2026
 
Baxfendy (baxdrostat) recommended for approval in the EU for the treatment of adults with hypertension
 
Based on Phase III results showing statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or resistant hypertension
 
Baxfendy 2mg lowered office systolic blood pressure by 15.7 mmHg from baseline in BaxHTN trial and 24-hour ambulatory systolic blood pressure by 16.6 mmHg from baseline in Bax24 trial
 
If approved, Baxfendy will be the first and only aldosterone synthase inhibitor in the EU  
 
AstraZeneca's Baxfendy (baxdrostat) has been recommended for approval in the European Union (EU) for the treatment of adults with arterial hypertension insufficiently controlled with at least two antihypertensive medicinal products. If approved, Baxfendy will be the first and only aldosterone synthase inhibitor (ASI) in the EU, directly targeting aldosterone to address a key biological driver of elevated blood pressure.
 
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from two pivotal Phase III trials in which Baxfendy demonstrated statistically significant and clinically meaningful reductions in seated systolic blood pressure (SBP) in patients with uncontrolled or resistant hypertension, and 24-hour average ambulatory SBP in patients with resistant hypertension.1,2
 
There are 1.4 billion people worldwide living with hypertension.3 Approximately 50% of people already taking two or more antihypertensive medications struggle with persistently uncontrolled hypertension.4,5 About 70 million adults across Europe have hypertension that remains uncontrolled despite treatment, putting them at increased risk for cardiovascular disease and premature death.3,6,7 Hypertension is the most prevalent and significant modifiable cardiovascular risk factor worldwide, accounting for more deaths and disability than any other modifiable risk.8-10 Elevated aldosterone levels play a central role in persistently uncontrolled hypertension and are associated with a decline in kidney function and increased cardiovascular risk.11-13
 
Dr. Bryan Williams, Chair of Medicine at University College London and primary investigator for BaxHTN and Bax24, said: "The strength of the research behind Baxfendy is a triumph of science and demonstrates its potential as an important new class of treatment for people in Europe living with persistently uncontrolled hypertension. Epidemiological data indicate that a 10 mmHg decrease in systolic blood pressure is associated with a roughly 20% lower risk of serious cardiovascular events like heart attack and stroke, underscoring why effective blood pressure lowering matters for people living with uncontrolled hypertension."
 
Ruud Dobber, Executive Vice President and President, BioPharmaceuticals Business Unit, AstraZeneca, said: "Hypertension is often called the 'silent killer' and is a leading risk factor for heart attack, stroke and dementia. This positive CHMP opinion for Baxfendy marks a significant step toward bringing this potential first-in-class innovation to patients in Europe. This novel medicine reflects the strength of our pipeline across interconnected cardiovascular, renal and metabolic diseases as we deliver on our 2030 ambition to bring 20 new medicines to the world."
 
In the BaxHTN Phase III trial,14 published in the New England Journal of Medicine,1 Baxfendy demonstrated statistically significant and clinically meaningful efficacy for the treatment of patients with hypertension on top of standard of care. At week 12, the absolute reduction from baseline in mean seated SBP was 15.7 mmHg (95% confidence interval [CI], -17.6 to -13.7) and the placebo-adjusted reduction was 9.8 mmHg (95% CI, -12.6 to -7.0; p<0.001) for the 2mg dose.
 
In the Bax24 Phase III trial,15 published in The Lancet,2 Baxfendy demonstrated statistically significant, clinically meaningful and consistent blood pressure reductions in patients with resistant hypertension who received baxdrostat 2mg or placebo on top of standard of care. At week 12, the absolute reduction from baseline in ambulatory 24-hour average SBP was 16.6 mmHg (95% CI, -18.8 to -14.3) and the placebo-adjusted reduction was 14.0 mmHg (95% CI, -17.2, -10.8; p<0.0001). Efficacy was observed throughout the 24-hour period, including early morning, when patients with hypertension are at a higher risk of cardiovascular events.16,17
 
Baxfendy was generally well-tolerated in the trials, with no unanticipated safety findings.
 
Baxfendy is approved in the US and other countries as a first-in-class ASI for adults with hypertension not adequately controlled on other therapies, with regulatory filings currently under review in other major regions, including Japan and China.
 
Baxfendy is a first-in-class, highly selective and potent ASI designed to lower blood pressure in a new way by specifically inhibiting the production of aldosterone,18 a hormone that raises blood pressure to unhealthy levels and increases the risk of heart and kidney problems.11-13
 
Notes
 
Persistently uncontrolled hypertension
 
Hypertension is a medical condition characterised by consistently high blood pressure levels, affecting an estimated 1.4 billion people worldwide.3,19,20 Over time, this can damage blood vessels and vital organs, increasing the risk of serious health problems such as heart attack, stroke, heart failure and kidney disease. 19,20
 
Treated but uncontrolled patients with hypertension are at a significantly greater risk of all-cause mortality, heart-disease specific mortality, stroke-related mortality, CVD-specific mortality and dementia than patients whose hypertension is controlled. A large meta-analysis found that lowering systolic blood pressure by 10 mmHg can reduce the risk of major adverse cardiovascular events by around 20%,21 underscoring the urgent need for new treatments that target a key hypertension pathway at its source.
 
An observational study of nearly 60,000 patients studied over a median of 9.7 years showed that a 9.5 mmHg increase in SBP was associated with a 30% increase in risk of all-cause mortality and 41% increase in risk of cardiovascular death.22 Studies have shown that increased night-time blood pressure is associated with higher cardiovascular risk,23,24 and patients with hypertension have a higher risk of cardiovascular events like heart attack, stroke and death around the time of their morning blood pressure surge.16,17 Epidemiological data indicate that a 10 mmHg decrease in SBP is associated with a roughly 20% lower risk of serious cardiovascular events.21
 
Uncontrolled hypertension refers to persistently elevated blood pressure despite the use of two or more medications, while resistant hypertension, a more severe form, remains elevated despite treatment with three or more medications. Guidelines currently recommend that in patients with hypertension, treated BP values should be targeted to 130/80 mmHg or lower in most patients.19,25
 
Aldosterone, a hormone that can raise blood pressure to unhealthy levels by promoting sodium and water retention,11,12 is a key contributor to persistently uncontrolled hypertension. Elevated aldosterone levels, along with factors such as obesity, high salt intake and various genetic or secondary conditions,26 are strongly associated with poor blood pressure control and the progression of heart failure and kidney disease. When left untreated, hypertension significantly increases the risk of cardiovascular and kidney-related complications.8,19,25
 
BaxHTN trial
 
The BaxHTN Phase III trial14 had three different evaluation periods that supported the following endpoints: The primary endpoint was assessed during a 12-week double-blind, placebo-controlled period. A total of 796 patients were randomised in a 1:1:1 ratio to receive Baxfendy 2mg, 1mg or placebo once daily on top of standard of care [two antihypertensive agents at baseline, one of which is a diuretic for uncontrolled hypertension and ≥ 3 antihypertensive agents at baseline, one of which is a diuretic for resistant hypertension]. The primary efficacy endpoint was the difference in mean change from baseline in seated SBP at week 12 between participants treated with Baxfendy (2mg or 1mg separately) and participants treated with placebo.
 
Persistence of efficacy was assessed during a randomised withdrawal period from week 24 to week 32. Approximately 300 patients treated with Baxfendy 2mg were re-randomised in a 2:1 ratio to either continue receiving baxdrostat 2mg or placebo for the 8 weeks. SBP at the end of the 8 weeks was compared between placebo and the Baxfendy 2mg dose. Long-term safety was assessed at the end of the study (Week 52 followed by a 2-week safety follow-up visit) compared to a standard-of-care arm and was consistent with that observed during the 12-week double-blind treatment period. In a post-hoc efficacy analysis on the clinically meaningful reductions in seated SBP with Baxfendy were sustained over 52 weeks with a placebo-adjusted reduction of 12.6 mmHg (95% CI, -16.7 to -8.5; p<0.001) for the 2 mg dose.1
 
Additional confirmatory secondary endpoints include the effect of Baxfendy versus placebo on seated SBP at week 12 in the resistant hypertension subpopulation, the effect of Baxfendy versus placebo on seated diastolic blood pressure at week 12, and proportion of participants achieving seated SBP less than 130 mmHg at week 12.
 
Bax24 trial
 
The Bax24 Phase III trial15 was a randomised, double-blind, placebo-controlled, parallel group study to evaluate the effects of 2mg Baxfendy versus placebo, administered once a day (QD) orally, on the reduction of ambulatory SBP, as well as safety and tolerability in participants with resistant hypertension. A total of 218 patients were randomised in a 1:1 ratio to receive Baxfendy 2mg or placebo once daily during a 12-week double-blind period. The primary efficacy endpoint was the change from baseline in ambulatory 24-hour average SBP at Week 12.
 
Consistent 24-hour blood pressure control is an important clinical outcome in patients with persistently uncontrolled hypertension. Multiple studies have demonstrated that 24-hour blood pressure is a more powerful predictor of cardiovascular events than a clinic-based measurement.22 When 24-hour average systolic blood pressure rises by 9.5 mmHg, the associated risk of all-cause mortality increases by 30%.22
 
Additional secondary endpoints include the effect of baxdrostat versus placebo on change from baseline in ambulatory night-time average SBP, change from baseline in ambulatory daytime average SBP, change from baseline in seated SBP, the number of participants achieving ambulatory 24-hour average SBP of less than 130 mmHg, change from baseline in ambulatory 24-hour average diastolic blood pressure (DBP), change from baseline in ambulatory night-time average DBP, change from baseline in the average ambulatory daytime average DBP, change from baseline on seated DBP and the number of participants achieving a nocturnal SBP dipping of greater than or equal to 10%, all measured at Week 12. Occurrence of adverse events was evaluated during the 12-week treatment period as well as during a 2-week safety follow-up period.
 
In a key secondary endpoint, 70.6 percent of patients treated with Baxfendy achieved ambulatory 24-hour average SBP of less than 130 mmHg compared to 16.7 percent of patients receiving placebo (Odds ratio 15.2 [95% CI 6.6, 35.2; p<0.0001]),2 in line with the 2024 ESH guidelines for the management of arterial hypertension.25 This corresponds to two patients needing treatment (NNT) with Baxfendy rather than placebo for one additional patient to achieve this blood pressure threshold at week 12.27
 
Baxfendy and the clinical development programme
 
Baxfendy is a first-in-class, highly selective and potent, oral, small molecule that inhibits aldosterone synthase,18 an enzyme encoded by the CYP11B2 gene, which is responsible for the synthesis of aldosterone in the adrenal gland.12 In clinical trials, Baxfendy was observed to significantly lower aldosterone levels without affecting cortisol levels across a wide range of doses.28,29
 
As part of a broad development programme, Baxfendy is currently being investigated in clinical trials in other conditions where high aldosterone plays a role in elevating cardiorenal risk, including as a monotherapy for primary aldosteronism,30 and in combination with dapagliflozin for chronic kidney disease and hypertension,31,32 and the prevention of heart failure in patients with hypertension.33
 
AstraZeneca acquired Baxfendy through its purchase of CinCor Pharma, Inc. in February 2023.34
 
AstraZeneca in CVRM
 
Cardiovascular, Renal and Metabolism (CVRM), part of BioPharmaceuticals, forms one of AstraZeneca's main disease areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys, liver and pancreas, AstraZeneca is investing in a portfolio of medicines for organ protection by slowing or stopping disease progression, and ultimately paving the way towards regenerative therapies. The Company's ambition is to improve and save the lives of millions of people, by better understanding the interconnections between CVRM diseases and targeting the mechanisms that drive them, so we can detect, diagnose and treat people earlier and more effectively.
 
AstraZeneca
 
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.
 
Contacts
 
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
References
 
1.
Flack JM, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025. Aug 30:10.1056/NEJMoa2507109. doi: 10.1056/NEJMoa2507109.
2.
Azizi M, Bax24 investigators, et al. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2026 Mar 7;407(10532):988-999.
3.
World Health Organization. Global report on hypertension 2025: high stakes: turning evidence into action. 2025. https://iris.who.int/handle/10665/382841. Accessed September 2025
4.
Carey RM, et al. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2019;73(2):424-431.
5.
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021 Sep 11;398(10304):957-980.
6.
Rapsomaniki E, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014 May 31;383(9932):1899-911.
7.
GBD 2019 Risk Factors Collaborators. Lancet. 2020;396:1223-1249.
8.
Zhou D, et al. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study. Sci Rep. 2018: 20;8(1):9418.
9.
Hall ME et al. Weight-loss strategies for prevention and treatment of hypertension: a scientific statement from the American Heart Association. Hypertension. 2021;78:e38-e50.
10.
GBD 2023 Disease and Injury and Risk Factor Collaborators. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406:1873-1922.
11.
Inoue K, et al. Serum aldosterone concentration, blood pressure, and coronary artery calcium: the Multi-Ethnic Study of Atherosclerosis [including online supplement]. Hypertension. 2020;76(1):113-120.
12.
Cannavo A, et al. Aldosterone and mineralocorticoid receptor system in cardiovascular physiology and pathophysiology. Oxid Med Cell Longev. 2018;2018:1204598.
13.
Xanthakis V, Vasan RS. Aldosterone and the risk of hypertension. Curr Hypertens Rep. 2013;15(2):102-107.
14.
ClinicalTrials.gov. A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension (BaxHTN). Available at: https://clinicaltrials.gov/study/NCT06034743. Accessed April 2026.
15.
ClinicalTrials.gov. A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension (Bax24). Available at: https://clinicaltrials.gov/study/NCT06168409. Accessed April 2026.
16.
Renna NF, et al. Morning blood pressure surge as a predictor of cardiovascular events in patients with hypertension. Blood Press Monit. 2023;28(3):149-157.
17.
Kario K et al. Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients. Hypertens Res. 2006;29(8):581-7.
18.
Bogman K, et al. Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2). Hypertension. 2017;69:189-96.
19.
McEvoy JW, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J.2024;45(38):3912-4018.
20.
Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary. Hypertension. 2018;71(6):1269-1324.
21.
Ettehad D, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-67.
22.
Staplin N, et al. Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients. Lancet. 2023;401(10393):2041-2050.
23.
Narita K, et al. Nighttime Home Blood Pressure Is Associated With the Cardiovascular Disease Events Risk in Treatment-Resistant Hypertension. Hypertension. 2022;79(2):e18-e20.
24.
Niiranen TJ, Mäki J, Puukka P, Karanko H, Jula AM. Office, home, and ambulatory blood pressures as predictors of cardiovascular risk. Hypertension. 2014 Aug;64(2):281-6.
25.
Kreutz R, et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med. 2024 Aug;126:1-15.
26.
van Oort S, et al. Association of cardiovascular risk factors and lifestyle behaviors with hypertension: a mendelian randomization study. Hypertension. 2020;76(6):1971-1979.
27.
Williams B, et al. Effect of baxdrostat on 24-hour ambulatory blood pressure in patients with resistant hypertension: the Bax24 trial. Presented at: American Heart Association Scientific Sessions 2025; November 7–10, 2025; New Orleans, LA.
28.
Freeman MW, et al. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res. 2023;46(1):108-118.
29.
Freeman MW, et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388(5):395-405.
30.
ClinicalTrials.gov. A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism (BaxPA). Available at: https://clinicaltrials.gov/study/NCT07007793. Accessed April 2026.
31.
ClinicalTrials.gov. A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. Available at: https://clinicaltrials.gov/study/NCT06268873. Accessed April 2026.
32.
ClinicalTrials.gov. A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (BaxDuo-Pacific). Available at: https://clinicaltrials.gov/study/NCT06742723. Accessed April 2026.
33.
ClinicalTrials.gov. Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin (Prevent-HF). Available at: https://clinicaltrials.gov/study/NCT06677060. Accessed April 2026.
34.
AstraZeneca 2023. Acquisition of CinCor Pharma complete. Available at: https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-acquires-cincor-for-cardiorenal-asset.html. Accessed April 2026.
 
 
Matthew Bowden
Company Secretary
AstraZeneca PLC
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
  
Date: 16 November 2026
 
 
By: /s/ Matthew Bowden
 
Name: Matthew Bowden
 
Title: Company Secretary

Keep reading